Recombinant Bovine Somatotropin vs Sucralose: which is worse?

What is Recombinant Bovine Somatotropin?

Recombinant bovine somatotropin (rBST) is the synthetic version of bovine growth hormone (BST), naturally produced by the pituitary gland in cattle. The recombinant version is produced using genetically engineered bacteria and is injected into dairy cows to increase milk production by 10-15%. Brand name: Posilac.

What is Sucralose?

Sucralose is a synthetic non-caloric sweetener made by selectively chlorinating three hydroxyl groups in sucrose (table sugar). Despite being derived from sugar, the chlorination makes it non-digestible: most passes through the body without being metabolized. It is approximately 600 times sweeter than sucrose.

Documented risks

Recombinant Bovine Somatotropin: See recombinant-bovine-growth-hormone-rbgh for full detail. Key concerns: rBST elevates IGF-1 in milk; elevated blood IGF-1 is associated with breast, prostate, and colorectal cancer risk in epidemiological studies. Animal welfare: increased mastitis (up to 25-50% higher rates), lameness, and antibiotic use. The Codex Alimentarius Commission declined to endorse rBST safety MRLs in a historic 33-29 vote. Health Canada rejected rBST approval in 1999 after finding it caused significant animal health problems requiring increased antibiotic use.

Sucralose: A 2023 study published in Nature Medicine found that sucralose-1,6-hexanediacid — a gut-derived metabolite of sucralose — enhanced T-cell immune activity in vitro. The researchers found that sucralose exposure in certain doses could potentially affect immune function. However, this was an early-stage study and its clinical implications for humans are not established. A 2021 Cell study found that sucralose and other non-nutritive sweeteners altered gut microbiome composition and glucose tolerance in human participants who were non-habitual sweetener users. The study found sucralose consumption was associated with glucose intolerance changes in some individuals, suggesting gut microbiome-mediated effects on metabolism. A 2016 study in the International Journal of Occupational and Environmental Health found sucralose consumption was associated with higher leukemia incidence in male mice at high lifetime doses. This finding prompted significant concern, though regulators noted the doses used far exceeded typical human intake. Chlorinated compounds: sucralose contains chlorine atoms in its structure. Critics have argued this makes it similar to organochlorine compounds, some of which are known carcinogens. Regulatory agencies have reviewed this and do not consider the chlorine in sucralose equivalent to organochlorine pollutants; the chlorinated positions are not metabolically active. However, high-temperature cooking with sucralose can generate chlorinated compounds. EFSA's 2017 re-evaluation concluded sucralose is safe and non-carcinogenic at its ADI of 15 mg/kg body weight. The FDA ADI of 5 mg/kg/day provides a substantial safety margin relative to typical consumer intake from Splenda use.